药智官方微信 药智官方微博
客服 反馈
首页 > 特色要素 > 原料药 > xl184

企业名片

  • 武汉纽拜尔医药科技有限公司
    • 联系人:赵经理
    • 联系方式:立即查看
    • 地址:武汉市东湖新技术开发区光谷一路225号实验附属楼2楼204室

    该供应商其他商机

    xl184

    • 药智价格:
      询价
    • 货源类别:
      无现货
    • 发布时间:
      2015-12-10 10:55:45
    • 供  应 商:
      武汉纽拜尔医药科技有限公司
    • 供应分类:
      原料药
    分享到:
    • xl184
    
                    

    产品名称:卡博替尼苹果酸盐

    产品别名:Cabozantinib malate (XL184)

    CAS.NO:1140909-48-3

    分子式:C28H24FN3O5.C4H6O5

    分子量:635.59

    稳定性:3年 -20℃粉状 6个月-80℃溶于溶剂

    产品描述:Cabozantinib malate (XL184)是Cabozantinib的苹果酸盐,是有效的VEGFR2抑制剂,IC50为0.035 nM,也抑制c-Met, Ret, Kit, Flt-1/3/4, Tie2和AXL,无细胞试验中IC50分别为1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM和7 nM。

    靶点:VEGFR2/KDR [1] c-Met [1] Kit [1] VEGFR3/FLT4 [1] Axl [1]

    体外研究:Cabozantinib has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] Cabozantinib at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. Cabozantinib also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although Cabozantinib has no significant effect on MPNST cell growth at 0.1 μM, Cabozantinib at 5-10 μM significantly inhibits the MPNST cell growth. [2]

    体内研究:Cabozantinib treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. Cabozantinib also decreases invasiveness of primary tumors and reduces metastasis. [1] Cabozantinib at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of Cabozantinib induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of Cabozantinib is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]

    特征:


    还未收到相关的询价信息

    在线询价

    您正在向武汉纽拜尔医药科技有限公司发送关于产品xl184的询问

    *联系人:
    当前还未登录,登录后可在线询价,马上登录注册
    *联系电话:
    *验证码:
    *采购数量:
    *有效时间:

    若供应商超过3天未报价,委托药智通推荐更多供应商报价
    说明:

    点击“立即发送”后,商家将在1个工作日内与您取得联系。